Incyte is seeking collaborations in HIV, oncology, diabetes, inflammation
Incyte Corp. business development
Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. They have an experienced management and discovery team. Their assets, experience and prior success in bringing important new drugs to market puts them in a strong position to make a difference in healthcare, improve the lives of patients and build significant sustainable value for their shareholders.
To succeed in their objective to create a pipeline of novel, orally available drugs that address serious unmet medical needs, they have established a broad range of discovery capabilities in-house, including target validation, high-throughput screening, medicinal chemistry, computational chemistry, and pharmacological and ADME (absorption, distribution, metabolism and excretion) assessment. They augment these capabilities through collaborations with academic and contract laboratory resources with relevant expertise.
They select drug targets with strong preclinical or clinical validation in areas where they have the potential to generate either first-in-class molecules or compounds that are highly differentiated from existing treatments.
Focus of interest are: